Improving Delivery Efficiency & Unlocking New Indications Through Antibody-Fragment Conjugates

1:30 pm - Wednesday 18th March 2026

  • Antikor’s platform for recombinant antibody fragments optimized for developability and payload bioconjugation
  • Process for Antibody Fragment Drug Conjugate (FDC) discovery, tailoring the linker-payload
  • Update on ANT-045, our lead FDC program for cMET-expressing solid tumours
  • An insight into Antikor’s follow up projects

Speakers:

Mahendra Deonarain
Chief Executive, Science & Operating Officer
Antikor